Market News & Trends
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
Avalo Therapeutics, Inc. recently announced that the Investigational New Drug (IND) for AVTX-009, an anti-IL-1β monoclonal antibody (mAb), for the treatment of hidradenitis suppurativa (HS)…
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Athira Pharma, Inc recently announced the completion of dosing for the last patient in the Phase 2/3 LIFT-AD clinical trial evaluating fosgonimeton in people with…
Prelude Therapeutics Announces Clinical Collaboration With Merck
Prelude Therapeutics Incorporated recently announced it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the US…
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase 1/2 Trials for Huntington’s Disease Treatment
uniQure N.V. recently announced updated interim data including up to 24 months of follow-up data from 29 treated patients enrolled in the ongoing US and…
Obsidian Therapeutics Announces FDA Fast Track Designation for Advanced Melanoma Treatment
Obsidian Therapeutics, Inc. recently announced the US FDA has granted Fast Track Designation to OBX-115, a novel engineered tumor-derived autologous T cell immunotherapy (tumor-infiltrating lymphocyte…
Zevra Announces FDA Advisory Committee Meeting to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
Zevra Therapeutics, Inc. recently announced the US FDA has indicated that it will convene a meeting with the recently formed Genetic Metabolic Diseases Advisory Committee…
Skinvisible Unveils Promising Data on Transdermal Obesity Formulations
Skinvisible Pharmaceuticals, Inc. recently announced exciting data demonstrating its transdermal delivery of obesity drugs (and other glucose-controlling drugs), including a GLP-1 agonist and CB-1 receptor…
MedPharm & Tergus Pharma Merger Forms Topical & Transepithelial CDMO Leader
MedPharm, Ltd., an Ampersand Capital Partners portfolio company, and Tergus Pharma, a Great Point Partners portfolio company, recently announced a merger. The combined topical and…
Triclinic Labs, Inc. & ELDICO Scientific Announce Microcrystal Electron Diffraction Partnership
The two companies recently announced an exclusive strategic collaboration to introduce Microcrystal Electron Diffraction services and instruments to the North American market. Microcrystal Electron Diffraction…
RS BioTherapeutics Announces Research Collaboration With University of Colorado School of Medicine
RS BioTherapeutics recently announced a collaboration agreement with the University of Colorado School of Medicine to evaluate use of its first-in-class, steroid-free therapeutic platform in…
Iktos Acquires Synsight, a Company Specializing in Protein-Protein & RNA-Protein Interactions-Targeted Drug Discovery
Iktos recently announced the acquisition of Synsight, a French biotech company applying AI and high-content cell imaging to the discovery of novel drug candidates. The…
CellProthera & BioCardia Collaborate on Successful Phase 2 Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction
CellProthera and BioCardia Inc. recently announced success from a collaborative Phase 2 trial of ProtheraCytes for the treatment of acute myocardial infarction (AMI) led by…
HilleVax Reports Topline Data From NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants
HilleVax, Inc. recently announced topline data results from NEST-IN1. NEST-IN1 is a Phase 2b, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy, safety, and…
CERo Therapeutics Presents CER-1236 Data Supporting Use in AML
CERo Therapeutics Holdings, Inc. recently announced the presentation of a poster on its lead compound CER-1236 at the Global Cell & Gene Therapy Summit 2024.…
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical-Stage Pharmaceutical Portfolio to Publicly Traded Company
SciSparc Ltd. recently announced it signed a non-binding letter of intent (LOI) to spin off its advanced clinical-stage pharmaceutical portfolio and its equity stake in…
Silo Pharma Announces Exclusive Global License for Lead Candidate
Silo Pharma, Inc. recently announced it has entered into an exclusive, global license agreement with Columbia University to further develop, manufacture, and commercialize its lead…
CureVac Initiates Strategic Restructuring to Align Resources With Focus on High-Value mRNA Pipeline Opportunities
CureVac N.V. recently announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet…
Pentixapharm Acquires Target Discovery Business of Glycotope
Pentixapharm AG recently announced the execution of an agreement, effective July 1, to acquire the target discovery business of Berlin-based Glycotope GmbH. The deal encompasses…
Medigene AG Expands Patent Portfolio With the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor
Medigene AG recently announced it has been issued a patent by the Chinese Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York…
IntelGenx Obtains Preliminary Efficacy Results for the BUENA Montelukast VersaFilm Phase 2a Clinical Trial in Patients With Mild to Moderate Alzheimer’s Disease
IntelGenx Corp. has successfully completed the BUENA Alzheimer’s disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to…
